Volume: 10 Issue: 1
Year: 2022, Page: 3-10, Doi: https://doi.org/10.47799/pimr.1001.02
Received: Dec. 11, 2021 Accepted: Jan. 21, 2022 Published: Jan. 21, 2022
Hypertension is one of the most important risk factors for the development of ischemic heart diseases, stroke, disability, vascular dementia, heart failure, renal dysfunction, retinopathy, and premature death. Despite the use of two or more blood pressure lowering medications, a considerable proportion of patients show poor control. Current antihypertensive medications show the limitation of use and effect in obese population, certain races like black population and also in renal impairment. Thus, there is an impending need to develop novel classes of antihypertensive agents acting on new targets with diversified mechanisms of action to more effectively manage raised blood pressure. With the introduction of the recent concept of overactive brain renin angiotensin system in cardiovascular disorders, attempts have been made to identify a molecule with the potential of inhibiting aminopeptidases involved in the formation of Angiotensin III. A novel aminopeptidase A inhibitor, also a prodrug Firibastat is currently undergoing development in Phase III clinical trials for hypertension as well as chronic heart failure. We hereby, provide an updated summary of evidence generated so far with Firibastat and also a glimpse into the therapeutic potential of this novel candidate extending beyond the spectrum of essential hypertension
Keywords: obese, Fibribastat, Hypertension, Heart failure, Obese, Central Aminopeptidase A Inhibitor, Resistant Hypertension
Keck, M, Hmazzou, R & Llorens-Cortes, C . 2019. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions. CurrHypertens Rep 21(7):50.
Arendse, L B, Danser, Ahj, Poglitsch, M, Touyz, R M, Burnett, J C, Llorens-Cortes, C, Ehlers, M R & Sturrock, E D . 2019. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev 71(4):539–70.
Ferdinand, K C, Balavoine, F, Besse, B, Black, H R, Desbrandes, S & Dittrich, H C . 2019. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation 140(2):138–184.
Llorens-Cortes, C & Touyz, R M . 2020. Evolution of a New Class of Antihypertensive Drugs: Targeting the Brain Renin-Angiotensin System. Hypertension 75(1):6–15.
Balavoine, F, Azizi, M, Bergerot, D, Mota, De, Patouret, N, Roques, R & B P . 2014. Llorens-Cortes C. Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. Clin Pharmacokinet 53(4):385–95.
2021. National Center for Biotechnology Information. PubChem Compound Summary for CID 73672048 Fibristat. https://pubchem.ncbi.nlm.nih.gov/compound/Firibastat
Marc, Y, Gao, J, Balavoine, F, Michaud, A, Roques, B P & Llorens-Cortes, C . 2012. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension 60(2):411–419.
Boitard, S E, Marc, Y, Keck, M, Mougenot, N, Agbulut, O, Balavoine, F & Llorens-Cortes, C . 2019. Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice. J Mol Cell Cardiol 127:215–237.
Azizi, M, Courand, P Y, Denolle, T, Delsart, P, Zhygalina, V, Amar, L, Lantelme, P, Mounier-Vehier, C, Mota, De, Balavoine, N, Llorens-Cortes, F & C . 2019. A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension. J Hypertens 37(8):1722–1730.
Bakris, George, Quantum Genomics SA. 2021. Firibastat in Treatment-resistant Hypertension (FRESH) https://www.clinicaltrials.gov/ct2/show/NCT04277884
2022. Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meetinghttps. //www.globenewswire.com/news-release/2021/08/27/2287568/0/en/Quantum-Genomics
Sinha, A D & Agarwal, R . 2019. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clin J Am Soc Nephrol 14(5):757–64.
2019. Firibastat Phase III to start by end of the year. Press release of Quantum Genomics. https://www.edisongroup.com/publication/firibastat-phase-iii-to-start-by-end-of-the-year/25253/
Quantum Genomics SA 2018. Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction (QUORUM) ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03715998?term=Firibastat&cond=Cardiovascular+Diseases&draw=2&rank=2
Leenen, Fhh, Ahmad, M, Marc, Y & Llorens-Cortes, C . 2019. Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction. J Cardiovasc Pharmacol 73(2):82–91.
Maheshwari N, Tayal V. Novel Class of Central Renin Angiotensin Aldosterone System Inhibitor: Firibastat. Perspectives in Medical Research. 2022;10(1):3-7 DOI: 10.47799/pimr.1001.02